Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity Completed Phase 1 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0028768 (Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01334177TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and NeckTreatment